Aegerion (AEGR) Lomitapide Briefing Docs Posted; FDA Panel Says More Patients Needed to Rule Out Cancer Risk
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Join SI Premium – FREE
Aegerion (Nasdaq: AEGR) shares are higher following the FDA posting briefing docs for its lomitapide mesylate caps in 5-, 10-, and 20-mg doses today.
The meeting for lomitapide with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will be on October 17th.
In brief, the Committee said Aegerion needs more patients to rule out cancer risk.
Shares of Aegerion are up 7 percent in early trading Monday.
The meeting for lomitapide with the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will be on October 17th.
In brief, the Committee said Aegerion needs more patients to rule out cancer risk.
Shares of Aegerion are up 7 percent in early trading Monday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- FDA clears path for Protagenic's PT00114 anxiety drug IND submission
- Harrow study shows Iheezo cuts discomfort after eye injections
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
